RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.

CONCLUSIONS: The combination of siG12D-LODER™ and chemotherapy is well tolerated, safe and demonstrated a potential efficacy in patients with LAPC. NCT01188785.
PMID: 26009994 [PubMed - as supplied by publisher]

Source: Oncotarget - May 28, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research